Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment ⊕
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Sumitomo Pharma
since
auto-detected in 1 stories
7 days ago
Shares of Japan's Sumitomo Pharma fell over 12% on the back of profit-taking after a specialist panel endorsed its iPS cell-based therapy for Parkinson's disease.
page 1 of 1